Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Read More
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Read More
Novo Nordisk A/S (NVO) M&A Call Transcript
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Harry Sephton - UBS Investment Bank, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Peter Verdult - BNP Paribas Exane, Research Division Conor MacKay - BMO Capital Markets Equity Research Michael Nedelcovych - …
Read More
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Published: October 09, 2025 by: Fast Company
Sentiment: Positive
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.
Read More
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
Published: October 09, 2025 by: Schaeffers Research
Sentiment: Positive
Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NASDAQ:AKRO) for as much as $5.2 billion in cash.
Read More
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Published: October 09, 2025 by: Benzinga
Sentiment: Neutral
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Read More
Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
Downgrading Novo Nordisk from a "Strong Buy" rating to a "Buy" rating, whereby it may or may not be able to overcome competition in the obesity drug development space. Company faces competition from Eli Lilly's Zepbound, but ongoing REDEFINE and EVOKE studies could restore market share and expand indications. Key pipeline assets include CagriSema, Cagrilintide, and Amycretin, with multiple late-stage trials aiming for superior weight loss and safety.
Read More
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Published: October 06, 2025 by: Schwab Network
Sentiment: Neutral
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview)
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and Alzheimer's trial data as critical catalysts that could restore confidence and drive a sustained stock recovery. The current valuation appears disconnected from NVO's growth prospects, supporting a 12-month price target of $65 and a longer-term target of $80.4.
Read More
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Read More
DEADLINE ALERT for NVO and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R.
Read More
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
The Truth About Novo Nordisk: 4 Myths That Don't Hold Up
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk remains a strong buy despite recent market pessimism, with key growth catalysts on the horizon. NVO's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss and offers superior cardiovascular benefits, maintaining competitive strength. Concerns over tariffs and compounded drugs are overblown; NVO's US manufacturing footprint and legal actions minimize these risks.
Read More
Here's Why Morgan Stanley Analysts Downgraded Novo Nordisk's Stock
Published: September 29, 2025 by: Investopedia
Sentiment: Negative
An analyst's concerns about demand for Novo Nordisk's blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Novo Nordisk A/S Investors
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S, ("Novo" or the "Company") (NYSE: NVO) investors of a class action on behalf of investors that bought securities between May 7, 2025, and July 28, 2025, inclusive (the “Class Period”). Novo investors have until September 30, 2025 to file a lead plaintiff motion.
Read More
NVO Slides on Morgan Stanley Downgrade, Case for Value Trade
Published: September 29, 2025 by: Schwab Network
Sentiment: Negative
Morgan Stanley now holds the most pessimistic view of Novo Nordisk's (NVO) stock. It downgraded the company to underweight from equal weight and set a Street-low price target of $47.
Read More
Deadline Soon: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: September 29, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 30, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO PARTICIPATE IN THE SECURITIE.
Read More
NOVO URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
Published: September 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Novo allegedly overstated GLP-1 growth; stock plunged 21.8% on July 29, 2025 after lowering outlook due to compounded drugs, weak expansion, competition.
Read More
Novo Nordisk Stock Is Downgraded. There's a ‘Tough Path Ahead.
Published: September 29, 2025 by: Barrons
Sentiment: Negative
U.S. prescriptions for Novo's Ozempic and Wegovy drugs are stagnating, Morgan Stanley analysts said.
Read More
Novo Nordisk: Leading bank downgrades drug marker, shares down 2%
Published: September 29, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) has been knocked back by Morgan Stanley, which has cut its rating on the Danish drugmaker from equal weight to underweight and lowered its price target from DKr 380 to DKr 300. The shares fell 2% to DKr 341.95 in Copenhagen after the note landed.
Read More
Novo Nordisk A/S (NVO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Sept. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
Read More
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
Published: September 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Novo (NVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Published: September 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Deadline Alert: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).
Read More
Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Read More
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406